For new drugs or vaccines, the evidence from one or more Phase III trials, taken together with the results of the Phase I and II trials, will be presented to licensing authorities to register the product for clinical or public health use. However, the total number of participants included in Phase I to III trials of a new product will often be no more than a few thousand, and there are usual…